These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
574 related articles for article (PubMed ID: 31346605)
21. Cardiomyocytes, cardiac endothelial cells and fibroblasts contribute to anthracycline-induced cardiac injury through RAS-homologous small GTPases RAC1 and CDC42. Kücük P; Abbey L; Schmitt J; Henninger C; Fritz G Pharmacol Res; 2024 May; 203():107165. PubMed ID: 38561112 [TBL] [Abstract][Full Text] [Related]
22. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Li K; Sung RY; Huang WZ; Yang M; Pong NH; Lee SM; Chan WY; Zhao H; To MY; Fok TF; Li CK; Wong YO; Ng PC Circulation; 2006 May; 113(18):2211-20. PubMed ID: 16651473 [TBL] [Abstract][Full Text] [Related]
23. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. Kim KH; Oudit GY; Backx PH J Pharmacol Exp Ther; 2008 Jan; 324(1):160-9. PubMed ID: 17928571 [TBL] [Abstract][Full Text] [Related]
24. Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. Li M; Sala V; De Santis MC; Cimino J; Cappello P; Pianca N; Di Bona A; Margaria JP; Martini M; Lazzarini E; Pirozzi F; Rossi L; Franco I; Bornbaum J; Heger J; Rohrbach S; Perino A; Tocchetti CG; Lima BHF; Teixeira MM; Porporato PE; Schulz R; Angelini A; Sandri M; Ameri P; Sciarretta S; Lima-Júnior RCP; Mongillo M; Zaglia T; Morello F; Novelli F; Hirsch E; Ghigo A Circulation; 2018 Aug; 138(7):696-711. PubMed ID: 29348263 [TBL] [Abstract][Full Text] [Related]
25. Concomitant low-dose doxorubicin treatment and exercise. Sturgeon K; Schadler K; Muthukumaran G; Ding D; Bajulaiye A; Thomas NJ; Ferrari V; Ryeom S; Libonati JR Am J Physiol Regul Integr Comp Physiol; 2014 Sep; 307(6):R685-92. PubMed ID: 25009215 [TBL] [Abstract][Full Text] [Related]
26. Klotho attenuated Doxorubicin-induced cardiomyopathy by alleviating Dynamin-related protein 1 - mediated mitochondrial dysfunction. Zhuang X; Sun X; Zhou H; Zhang S; Zhong X; Xu X; Guo Y; Xiong Z; Liu M; Lin Y; Zhang M; Liao X Mech Ageing Dev; 2021 Apr; 195():111442. PubMed ID: 33539906 [TBL] [Abstract][Full Text] [Related]
27. Loss of Mrp1 Potentiates Doxorubicin-Induced Cytotoxicity in Neonatal Mouse Cardiomyocytes and Cardiac Fibroblasts. Zhang W; St Clair D; Butterfield A; Vore M Toxicol Sci; 2016 May; 151(1):44-56. PubMed ID: 26822305 [TBL] [Abstract][Full Text] [Related]
28. An antibody against L1 cell adhesion molecule inhibits cardiotoxicity by regulating persistent DNA damage. Nam JK; Kim AR; Choi SH; Kim JH; Choi KJ; Cho S; Lee JW; Cho HJ; Kwon YW; Cho J; Kim KS; Kim J; Lee HJ; Lee TS; Bae S; Hong HJ; Lee YJ Nat Commun; 2021 Jun; 12(1):3279. PubMed ID: 34078883 [TBL] [Abstract][Full Text] [Related]
29. GATA4-targeted compound exhibits cardioprotective actions against doxorubicin-induced toxicity in vitro and in vivo: establishment of a chronic cardiotoxicity model using human iPSC-derived cardiomyocytes. Karhu ST; Kinnunen SM; Tölli M; Välimäki MJ; Szabó Z; Talman V; Ruskoaho H Arch Toxicol; 2020 Jun; 94(6):2113-2130. PubMed ID: 32185414 [TBL] [Abstract][Full Text] [Related]
30. SIRT1 activation attenuates diastolic dysfunction by reducing cardiac fibrosis in a model of anthracycline cardiomyopathy. Cappetta D; Esposito G; Piegari E; Russo R; Ciuffreda LP; Rivellino A; Berrino L; Rossi F; De Angelis A; Urbanek K Int J Cardiol; 2016 Feb; 205():99-110. PubMed ID: 26730840 [TBL] [Abstract][Full Text] [Related]
31. Early Administration of Carvedilol Protected against Doxorubicin-Induced Cardiomyopathy. Chen YL; Chung SY; Chai HT; Chen CH; Liu CF; Chen YL; Huang TH; Zhen YY; Sung PH; Sun CK; Chua S; Lu HI; Lee FY; Sheu JJ; Yip HK J Pharmacol Exp Ther; 2015 Dec; 355(3):516-27. PubMed ID: 26511374 [TBL] [Abstract][Full Text] [Related]
32. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372 [TBL] [Abstract][Full Text] [Related]
34. Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival. Kosić M; Nešić Z; Glumac S; Vasić M; Pajović V; Savić B; Japundžić-Žigon N Biomed Pharmacother; 2022 Jan; 145():112411. PubMed ID: 34781149 [TBL] [Abstract][Full Text] [Related]
35. Sodium thiosulfate prevents doxorubicin-induced DNA damage and apoptosis in cardiomyocytes in mice. Mizuta Y; Tokuda K; Guo J; Zhang S; Narahara S; Kawano T; Murata M; Yamaura K; Hoka S; Hashizume M; Akahoshi T Life Sci; 2020 Sep; 257():118074. PubMed ID: 32673667 [TBL] [Abstract][Full Text] [Related]
36. MiR-15b-5p is Involved in Doxorubicin-Induced Cardiotoxicity via Inhibiting Bmpr1a Signal in H9c2 Cardiomyocyte. Wan GX; Cheng L; Qin HL; Zhang YZ; Wang LY; Zhang YG Cardiovasc Toxicol; 2019 Jun; 19(3):264-275. PubMed ID: 30535663 [TBL] [Abstract][Full Text] [Related]
37. Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1. Sun Z; Lu W; Lin N; Lin H; Zhang J; Ni T; Meng L; Zhang C; Guo H Biochem Pharmacol; 2020 May; 175():113888. PubMed ID: 32112883 [TBL] [Abstract][Full Text] [Related]
38. Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity. Zhu W; Reuter S; Field LJ Cardiovasc Res; 2019 Apr; 115(5):960-965. PubMed ID: 30423020 [TBL] [Abstract][Full Text] [Related]